Asterias Biotherapeutics Company Profile (NYSEMKT:AST)

Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "AST."

Asterias Biotherapeutics Inc (NYSEMKT:AST) released its earnings results on Monday, August, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.07. The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $1.14 million. Asterias Biotherapeutics had a negative return on equity of 86.25% and a negative net margin of 2,762.03%. View Asterias Biotherapeutics' Earnings History.

2 brokerages have issued 12 month price targets for Asterias Biotherapeutics' shares. Their predictions range from $10.00 to $10.00. On average, they expect Asterias Biotherapeutics' share price to reach $10.00 in the next year. View Analyst Ratings for Asterias Biotherapeutics.

Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:

• 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (3/21/2017)
• 2. FBR & Co analysts commented, "We are transferring coverage of Asterias Biotherapeutics, Inc. (AST) and maintaining our Outperform rating, but we are lowering our price target to $6 (from $10) to reflect a more conservative view. AST is developing therapies in an area of immense promise that can change the practice of medicine. However, the emerging field of regenerative medicine using stem cell therapy is accompanied by increased regulatory and clinical risk. The company’s lead program (AST-OPC1) is a pluripotent stem cell platform, a cell line derived from embryonic stem cells. Pluripotent stem cells are “master cells” and have the potential to differentiate into any cell type, as well as reproduce indefinitely. AST’s pluripotent stem cells, AST-OPC1, are differentiated into oligodendrocyte progenitor cells, which are glial cells in the central nervous system. AST-OPC1 is being developed for spinal cord injuries (SCIs) and is in a Phase I/IIa trial testing higher doses for safety and efficacy. There is no cure or effective therapy approved for SCI that can rehabilitate patients." (3/7/2017)

Some companies that are related to Asterias Biotherapeutics include Novavax (NVAX), Protagonist Therapeutics (PTGX), Codexis (CDXS), Curis (CRIS), Nabriva Therapeutics AG (NBRV), Horizon Discovery Group PLC (HZD), Organovo Holdings (ONVO), Organovo Holdings (ONVO), Advaxis (ADXS), Chromadex Corp (CDXC), Merrimack Pharmaceuticals (MACK), Compugen (CGEN), OncoMed Pharmaceuticals (OMED), Genocea Biosciences (GNCA), Pluristem Therapeutics (PSTI), GTx (GTXI), CTI BioPharma Corp. (CTIC) and Regulus Therapeutics (RGLS).

Asterias Biotherapeutics' management team includes the folowing people:

• Don M. Bailey, Chairman of the Board
• Michael H. Mulroy, President, Chief Executive Officer, Director
• Ryan Daniel Chavez, Chief Financial Officer, General Counsel
• Katharine E. Spink Ph.D., Chief Operating Officer, Executive Vice President
• Casey C. Case Ph.D., Senior Vice President - Research and Nonclinical Development
• Jane S. Lebkowski Ph.D., Chief Scientific Officer
• Edward D. Wirth III, Chief Medical Officer
• Stephen L. Cartt, Director
• Alfred D. Kingsley, Director
• Aditya P. Mohanty, Director

Shares of Asterias Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Asterias Biotherapeutics stock can currently be purchased for approximately $3.15.